Document is current
Any future updates will be listed below
-
Authors
Sevilla-Ortega, Carmen https://orcid.org/0000-0003-3072-9903
Angelina, Alba https://orcid.org/0000-0001-5282-9767
Martín-Cruz, Leticia https://orcid.org/0000-0002-2546-1183
Pérez-Diego, Mario https://orcid.org/0000-0002-9787-8922
Maldonado, Angel https://orcid.org/0009-0001-6964-1573
Lavín, Begoña https://orcid.org/0000-0003-4671-1089
Marcos-Ramiro, Beatriz
Pérez de Llano, Luis https://orcid.org/0000-0003-2652-6847
Gayá, Auba
Real, Francisco X. https://orcid.org/0000-0001-9501-498X
Conejero, Laura https://orcid.org/0000-0001-6515-9221
Subiza, José Luis
Palomares, Oscar https://orcid.org/0000-0003-4516-0369
-
Funding
Funding for this research was provided by:
Comunidad de Madrid (IND2019/BMD17182)
Ministerio de Economía y Competitividad (PID2020-114396RB-I00)
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 25 July 2025
First Online: 3 August 2025
Competing interests
: O.P. received research grants from MINECO, Ministerio de Ciencia e Innovación, Inmunotek S.L., Novartis, and AstraZeneca and fees for giving scientific lectures or participation in Advisory Boards from: AstraZeneca, Pfizer, GlaxoSmithKline, Inmunotek S.L, Novartis, Sanofi-Genzyme and Regeneron. J.L.S. is the founder and CEO of Inmunotek SL and C.S.-O. and L.C. are employees of Inmunotek S.L. The rest of authors have no conflict of interest to declare.
